Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL734005 | 1.00 | L3MBTL1 (0.57) | L3MBTL1LMNASMN1; SMN2SLC1A3SLC1A1 | |
| SCHEMBL734006 | 1.00 | L3MBTL1 (0.57) | L3MBTL1LMNASMN1; SMN2SLC1A3SLC1A1 | |
| SCHEMBL11758185 | 0.91 | HTT (0.58) | LMNASMN1; SMN2HTTTGM2KEAP1 | |
| SCHEMBL16533444 | 0.89 | LMNA (0.60) | L3MBTL1LMNASMN1; SMN2SLC1A3SLC1A1 | |
| SCHEMBL30214739 | 0.88 | L3MBTL1 (0.59) | L3MBTL1LMNASMN1; SMN2SLC1A3SLC1A1 | |
| SCHEMBL12605288 | 0.86 | LMNA (0.60) | L3MBTL1LMNASMN1; SMN2SLC1A3SLC1A1 | |
| SCHEMBL735799 | 0.86 | SLC1A3 (0.64) | L3MBTL1LMNASMN1; SMN2SLC1A3SLC1A1 | |
| SCHEMBL334927 | 0.86 | SLC1A3 (0.64) | L3MBTL1LMNASMN1; SMN2SLC1A3SLC1A1 | |
| SCHEMBL334926 | 0.86 | SLC1A3 (0.64) | L3MBTL1LMNASMN1; SMN2SLC1A3SLC1A1 | |
| SCHEMBL4194137 | 0.84 | LMNA (0.49) | L3MBTL1LMNASMN1; SMN2SLC1A3SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932633-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20210380570-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2021-12-09 | — | — | US | disclosed |
| WO-2019217307-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-11-14 | — | — | WO | disclosed |
| US-8138175-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2321285-A1 | DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| WO-2010012619-A1 | DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-04 | — | — | WO | disclosed |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380570-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | L3MBTL1 2112/4885LMNA 2991/4885SMN1; SMN2 4385/4885 |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | L3MBTL1 3694/4885LMNA 3760/4885SMN1; SMN2 4455/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | L3MBTL1 4640/4885LMNA 2984/4885SMN1; SMN2 4690/4885 |
| US-11932633-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | L3MBTL1 2112/4885LMNA 2991/4885SMN1; SMN2 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.